METABOLISM DRUGS MARKET ANALYSIS

Metabolism Drugs MarketSize and Trends

The global metabolism drugs market is estimated to be valued at US$ 7,685.0 million in 2022 and is expected to exhibit a CAGR of 6.3% during the forecast period (2022-2030).

Figure 1. Global Metabolism Drugs Market Share (%), by Therapy Type, 2022

The increasing product approval by regulatory authorities is expected to drive the growth of the global metabolism drugs market

The increasing product approval by regulatory authorities is expected to drive the growth of the global metabolism drugs market. For instance, on February 17, 2022, Agios Pharmaceuticals, Inc., a company in the field of cellular metabolism pioneering therapies for genetically defined diseases, announced that the U.S. Food and Drug Administration (FDA) has approved PYRUKYND (mitapivat) in the U.S. for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, debilitating, lifelong hemolytic anemia. PYRUKYND is a first-in-class, oral PK activator and the first approved disease-modifying therapy for hemolytic anemia in adults with pyruvate kinase (PK) deficiency disease.

Figure 2.Global Metabolism Drugs Market Share (%), by Region, 2022

Increasing research and development for developing metabolism drugs is expected to drive the market growth

Increasing research and development for development metabolism drugs is expected to drive the market growth over the forecast period. For instance, on May 15, 2020, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, announced positive initial data from the confirmatory third cohort and longer-term data from the first two cohorts of the ongoing Phase 1/2 study of DTX401, an adeno-associated virus (AAV) based gene therapy for the treatment of glycogen storage disease type Ia (GSDIa).